CHK1

CHK1
Name	Checkpoint kinase 1
Organism	Homo sapiens
Uniprot	O14757
Length	476 aa
Chromosomal location	11q24.2

CHK1

CHK1 is a serine/threonine protein kinase central to the eukaryotic DNA damage checkpoint and replication stress response. Discovered through genetic and biochemical screens, CHK1 coordinates cell cycle progression, DNA repair, and replication fork stability across diverse model systems, linking studies in Saccharomyces cerevisiae, Xenopus laevis, Drosophila melanogaster, and human cell lines such as HeLa and HEK293. Its activity integrates signals from key sensor and transducer proteins identified in work on ATR, ATM, Mec1, and Rad3 pathways.

Introduction

CHK1 was first characterized in genetic screens for checkpoint genes alongside landmark discoveries including ATM and ATR kinases. CHK1 orthologs were functionally analyzed in model organisms like Schizosaccharomyces pombe and Caenorhabditis elegans to elucidate conserved roles in S-phase and G2/M checkpoints. Subsequent biochemical and structural work in laboratories associated with institutions such as Cold Spring Harbor Laboratory and Max Planck Society expanded understanding of its regulation by upstream mediators including RAD9, RAD17, and claspin.

Structure and biochemical properties

The CHK1 protein comprises an N-terminal catalytic kinase domain and a regulatory C-terminal region. The kinase fold resembles other AGC and CAMK family kinases studied in contexts such as the Protein kinase A structural literature and shares conserved motifs (VAIK, HRD, DFG). Crystal and cryo-EM studies by groups at institutions like EMBL and University of California, San Francisco revealed autoinhibitory interactions between termini that modulate substrate access. Key phosphorylation sites reside in the regulatory region, analogous to activation loops characterized in SRC and MAPK1 family members. CHK1 phosphorylates substrates on serine/threonine residues within consensus motifs; prominent substrates include CDC25A, CDC25C, and RAD51, as delineated in biochemical assays from laboratories at National Institutes of Health and Stanford University.

Regulation and activation mechanisms

CHK1 activation is principally mediated by phosphorylation through the ATR kinase in response to single-stranded DNA and replication stress signals arising from lesions described in studies of agents like hydroxyurea and ultraviolet irradiation. Recruitment complexes comprising RPA, RAD17, RAD9-RAD1-HUS1 (9-1-1) clamp, and the mediator Claspin promote ATR-dependent phosphorylation of CHK1 at conserved residues. Additional regulation is achieved via ubiquitin-mediated proteasomal pathways involving E3 ligases studied in the context of SCF complexes and deubiquitylases investigated at institutions such as Massachusetts Institute of Technology. Cross-talk with checkpoint phosphatases including WIP1 and proteins characterized in cancer research such as p53 modulate CHK1 signalling dynamics described in translational studies at Memorial Sloan Kettering Cancer Center.

Cellular functions and role in DNA damage response

CHK1 enforces S-phase progression, stabilizes replication forks, and delays mitotic entry by phosphorylating and inhibiting CDC25 phosphatases, thereby affecting cyclin-dependent kinase complexes explored in foundational work at Harvard University and Yale University. Through phosphorylation of recombination and repair proteins like RAD51 and FANCD2, CHK1 facilitates homologous recombination, echoing observations from consortia such as the Human Genome Project and repair-centric labs at The Sanger Institute. In embryogenesis and developmental contexts studied in Xenopus and Drosophila models, CHK1-dependent checkpoints preserve genomic integrity during rapid cell cycles. CHK1 also modulates transcriptional responses via factors implicated in studies at Cold Spring Harbor Laboratory and links to replication origin firing regulated by complexes characterized at EMBL-EBI.

Clinical significance and disease associations

Aberrant CHK1 activity or expression contributes to genome instability syndromes and oncogenesis. Overexpression of CHK1 has been reported in malignancies including breast cancer, ovarian cancer, colorectal cancer, and acute myeloid leukemia in cohorts studied at centers such as MD Anderson Cancer Center and Johns Hopkins Hospital. Conversely, loss-of-function or hypomorphic variants correlate with increased sensitivity to replication stress and may influence developmental disorders examined in clinical genetics units at Great Ormond Street Hospital. CHK1’s interaction with tumor suppressors and oncogenes—such as BRCA1, MYC, and KRAS—has been implicated in therapeutic resistance and prognosis across multi-institutional cancer studies.

Therapeutic targeting and inhibitors

Given its central role in coping with replication stress, CHK1 is a therapeutic target in oncology. Small-molecule inhibitors developed by pharmaceutical companies and academic collaborations—examples emerging from research at Pfizer, AstraZeneca, GlaxoSmithKline, and academic spinouts—include compounds that entered clinical trials for combination therapy with DNA-damaging agents like cisplatin, gemcitabine, and ionizing radiation. Clinical trials at sites such as Royal Marsden Hospital and Mayo Clinic evaluated CHK1 inhibitors for synthetic lethality with defects in BRCA-mediated repair or oncogene-induced replication stress. Resistance mechanisms involve compensatory activation of pathways including ATR and cell-cycle kinases like WEE1, guiding combination strategies under investigation at translational centers including Fred Hutchinson Cancer Center.

Category:Proteins